Wall Street brokerages expect Heron Therapeutics Inc (NASDAQ:HRTX) to announce $9.00 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Heron Therapeutics’ earnings, with estimates ranging from $7.00 million to $10.00 million. Heron Therapeutics reported sales of $1.28 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 603.1%. The business is scheduled to report its next earnings results on Thursday, February 22nd.

On average, analysts expect that Heron Therapeutics will report full-year sales of $9.00 million for the current financial year, with estimates ranging from $27.71 million to $31.00 million. For the next fiscal year, analysts expect that the firm will report sales of $67.03 million per share, with estimates ranging from $65.00 million to $68.10 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover Heron Therapeutics.

A number of research analysts have commented on the stock. BidaskClub upgraded shares of Heron Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, January 20th. ValuEngine upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Mizuho reiterated a “buy” rating and set a $28.00 price target on shares of Heron Therapeutics in a research report on Tuesday, January 16th. Cantor Fitzgerald set a $31.00 price target on shares of Heron Therapeutics and gave the company a “buy” rating in a research report on Monday, January 15th. Finally, Zacks Investment Research cut shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 10th. Three analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $28.82.

In other news, VP Kimberly Manhard sold 7,584 shares of the firm’s stock in a transaction that occurred on Wednesday, January 10th. The shares were sold at an average price of $20.00, for a total value of $151,680.00. Following the transaction, the vice president now owns 7,584 shares in the company, valued at $151,680. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 19.93% of the stock is currently owned by company insiders.

Several institutional investors have recently modified their holdings of HRTX. Schwab Charles Investment Management Inc. grew its holdings in shares of Heron Therapeutics by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 170,555 shares of the biotechnology company’s stock worth $2,363,000 after purchasing an additional 1,026 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Heron Therapeutics by 7.4% in the second quarter. Bank of New York Mellon Corp now owns 204,857 shares of the biotechnology company’s stock worth $2,837,000 after purchasing an additional 14,086 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of Heron Therapeutics by 26.6% in the second quarter. Legal & General Group Plc now owns 11,354 shares of the biotechnology company’s stock worth $157,000 after purchasing an additional 2,383 shares during the last quarter. Swiss National Bank grew its holdings in shares of Heron Therapeutics by 8.1% in the second quarter. Swiss National Bank now owns 78,500 shares of the biotechnology company’s stock worth $1,087,000 after purchasing an additional 5,900 shares during the last quarter. Finally, Wells Fargo & Company MN grew its holdings in shares of Heron Therapeutics by 9.1% in the second quarter. Wells Fargo & Company MN now owns 43,162 shares of the biotechnology company’s stock worth $597,000 after purchasing an additional 3,583 shares during the last quarter. Hedge funds and other institutional investors own 98.37% of the company’s stock.

Shares of Heron Therapeutics (NASDAQ:HRTX) traded up $0.20 on Tuesday, reaching $20.50. 758,558 shares of the company were exchanged, compared to its average volume of 1,010,000. The stock has a market capitalization of $1,120.00, a P/E ratio of -5.41 and a beta of 1.87. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.12 and a quick ratio of 2.02. Heron Therapeutics has a 1-year low of $12.70 and a 1-year high of $24.80.

COPYRIGHT VIOLATION WARNING: “Zacks: Analysts Anticipate Heron Therapeutics Inc (HRTX) Will Announce Quarterly Sales of $9.00 Million” was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://theolympiareport.com/2018/02/11/zacks-analysts-anticipate-heron-therapeutics-inc-hrtx-will-announce-quarterly-sales-of-9-00-million.html.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.